Cargando…

Antibody titres decline 3-month post-vaccination with BNT162b2

Several studies reported on the humoral response in subjects having received the BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months post-vaccination are currently lacking and are important to drive the future vaccination strategy. The CRO-VAX HCP study is an ongoing...

Descripción completa

Detalles Bibliográficos
Autores principales: Favresse, Julien, Bayart, Jean-Louis, Mullier, François, Elsen, Marc, Eucher, Christine, Van Eeckhoudt, Sandrine, Roy, Tatiana, Wieers, Gregoire, Laurent, Christine, Dogné, Jean-Michel, Closset, Mélanie, Douxfils, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300930/
https://www.ncbi.nlm.nih.gov/pubmed/34232116
http://dx.doi.org/10.1080/22221751.2021.1953403
_version_ 1783726555158020096
author Favresse, Julien
Bayart, Jean-Louis
Mullier, François
Elsen, Marc
Eucher, Christine
Van Eeckhoudt, Sandrine
Roy, Tatiana
Wieers, Gregoire
Laurent, Christine
Dogné, Jean-Michel
Closset, Mélanie
Douxfils, Jonathan
author_facet Favresse, Julien
Bayart, Jean-Louis
Mullier, François
Elsen, Marc
Eucher, Christine
Van Eeckhoudt, Sandrine
Roy, Tatiana
Wieers, Gregoire
Laurent, Christine
Dogné, Jean-Michel
Closset, Mélanie
Douxfils, Jonathan
author_sort Favresse, Julien
collection PubMed
description Several studies reported on the humoral response in subjects having received the BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months post-vaccination are currently lacking and are important to drive the future vaccination strategy. The CRO-VAX HCP study is an ongoing multicentre, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals who had received two doses of the BNT162b2 mRNA COVID-19 vaccine. Two hundred individuals underwent a blood drawn within 2 days before the first vaccine dose. One-hundred and forty-two persons (71%) were categorized as seronegative at baseline while 58 (29%) were seropositive. Samples were then collected after 14, 28, 42, 56, and 90 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points. Using a one-compartment kinetics model, the time to maximum concentration was estimated at 36 ± 3 days after the first dose and the estimated half-life of antibodies was 55 days (95% CI: 37–107 days) in seronegative participants. In seropositive participants, the time to maximum concentration was estimated at 24 ± 4 days and the estimated half-life was 80 days (95% CI: 46–303 days). The antibody response was higher in seropositive compared to seronegative participants. In both seropositive and seronegative subjects, a significant antibody decline was observed at 3 months compared to the peak response. Nevertheless, the humoral response remained robust in all participants.
format Online
Article
Text
id pubmed-8300930
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-83009302021-08-09 Antibody titres decline 3-month post-vaccination with BNT162b2 Favresse, Julien Bayart, Jean-Louis Mullier, François Elsen, Marc Eucher, Christine Van Eeckhoudt, Sandrine Roy, Tatiana Wieers, Gregoire Laurent, Christine Dogné, Jean-Michel Closset, Mélanie Douxfils, Jonathan Emerg Microbes Infect Original Article Several studies reported on the humoral response in subjects having received the BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months post-vaccination are currently lacking and are important to drive the future vaccination strategy. The CRO-VAX HCP study is an ongoing multicentre, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals who had received two doses of the BNT162b2 mRNA COVID-19 vaccine. Two hundred individuals underwent a blood drawn within 2 days before the first vaccine dose. One-hundred and forty-two persons (71%) were categorized as seronegative at baseline while 58 (29%) were seropositive. Samples were then collected after 14, 28, 42, 56, and 90 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time points. Using a one-compartment kinetics model, the time to maximum concentration was estimated at 36 ± 3 days after the first dose and the estimated half-life of antibodies was 55 days (95% CI: 37–107 days) in seronegative participants. In seropositive participants, the time to maximum concentration was estimated at 24 ± 4 days and the estimated half-life was 80 days (95% CI: 46–303 days). The antibody response was higher in seropositive compared to seronegative participants. In both seropositive and seronegative subjects, a significant antibody decline was observed at 3 months compared to the peak response. Nevertheless, the humoral response remained robust in all participants. Taylor & Francis 2021-07-22 /pmc/articles/PMC8300930/ /pubmed/34232116 http://dx.doi.org/10.1080/22221751.2021.1953403 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Favresse, Julien
Bayart, Jean-Louis
Mullier, François
Elsen, Marc
Eucher, Christine
Van Eeckhoudt, Sandrine
Roy, Tatiana
Wieers, Gregoire
Laurent, Christine
Dogné, Jean-Michel
Closset, Mélanie
Douxfils, Jonathan
Antibody titres decline 3-month post-vaccination with BNT162b2
title Antibody titres decline 3-month post-vaccination with BNT162b2
title_full Antibody titres decline 3-month post-vaccination with BNT162b2
title_fullStr Antibody titres decline 3-month post-vaccination with BNT162b2
title_full_unstemmed Antibody titres decline 3-month post-vaccination with BNT162b2
title_short Antibody titres decline 3-month post-vaccination with BNT162b2
title_sort antibody titres decline 3-month post-vaccination with bnt162b2
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300930/
https://www.ncbi.nlm.nih.gov/pubmed/34232116
http://dx.doi.org/10.1080/22221751.2021.1953403
work_keys_str_mv AT favressejulien antibodytitresdecline3monthpostvaccinationwithbnt162b2
AT bayartjeanlouis antibodytitresdecline3monthpostvaccinationwithbnt162b2
AT mullierfrancois antibodytitresdecline3monthpostvaccinationwithbnt162b2
AT elsenmarc antibodytitresdecline3monthpostvaccinationwithbnt162b2
AT eucherchristine antibodytitresdecline3monthpostvaccinationwithbnt162b2
AT vaneeckhoudtsandrine antibodytitresdecline3monthpostvaccinationwithbnt162b2
AT roytatiana antibodytitresdecline3monthpostvaccinationwithbnt162b2
AT wieersgregoire antibodytitresdecline3monthpostvaccinationwithbnt162b2
AT laurentchristine antibodytitresdecline3monthpostvaccinationwithbnt162b2
AT dognejeanmichel antibodytitresdecline3monthpostvaccinationwithbnt162b2
AT clossetmelanie antibodytitresdecline3monthpostvaccinationwithbnt162b2
AT douxfilsjonathan antibodytitresdecline3monthpostvaccinationwithbnt162b2